Trazodone effectiveness in depression: impacts of trazodone extended release vs SSRIs on the health status and quality of life of patients with major depressive disorder
IntroductionEarly research on the pharmacotherapy for major depressive disorder (MDD) has largely focused on symptomatic improvements, whereas this focus has shifted to functioning and quality of life in recent years. Studies have confirmed that antidepressants generally improve the functional outco...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1525498/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832590792422588416 |
|---|---|
| author | Marcin Siwek Adrian Andrzej Chrobak Anna Julia Krupa Aleksandra Gorostowicz Andrzej Juryk Dominika Dudek |
| author_facet | Marcin Siwek Adrian Andrzej Chrobak Anna Julia Krupa Aleksandra Gorostowicz Andrzej Juryk Dominika Dudek |
| author_sort | Marcin Siwek |
| collection | DOAJ |
| description | IntroductionEarly research on the pharmacotherapy for major depressive disorder (MDD) has largely focused on symptomatic improvements, whereas this focus has shifted to functioning and quality of life in recent years. Studies have confirmed that antidepressants generally improve the functional outcomes in MDD, but very few works have compared the efficacies of specific drugs. The present work aims to compare the impacts of trazodone once-a-day extended-release (XR) vs selective serotonin reuptake inhibitors (SSRIs) on the health status and quality of life in MDD.MethodsData were gathered from 180 subjects through a naturalistic observation study of trazodone effectiveness in depression (TED) and analyzed. The TED study participants received trazodone XR of SSRIs in flexible doses for 12 weeks. The health status and health-related quality of life (HRQoL) were evaluated using the EQ-5D-5L tool at baseline as well as 2, 4, 8, and 12 weeks.ResultsAt baseline, the subjects treated with trazodone XR vs SSRIs presented similar health status profiles and HRQoL values with respect to the mobility, self-care, and anxiety/depression dimensions along with lower scores for the usual activities, pain/discomfort, overall HRQoL, and health status. Both trazodone XR and SSRIs improved the health status and HRQoL of the MDD patients at all subsequent timepoints. Compared to SSRIs, trazodone XR provided greater improvements in terms of the self-care, usual activities, pain/discomfort, and anxiety/depression measures and more often improved participant overall health status and HRQoL. More participants reported mixed changes in their health status and HRQoL in the SSRI group than the trazodone XR group.DiscussionHealth status and HRQoL improved in both treatment arms, with preferable scores in trazodone XR vs. SSRIs group. |
| format | Article |
| id | doaj-art-11201696ebb3450b9dae56829075635a |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-11201696ebb3450b9dae56829075635a2025-01-23T06:56:20ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-01-011510.3389/fphar.2024.15254981525498Trazodone effectiveness in depression: impacts of trazodone extended release vs SSRIs on the health status and quality of life of patients with major depressive disorderMarcin Siwek0Adrian Andrzej Chrobak1Anna Julia Krupa2Aleksandra Gorostowicz3Andrzej Juryk4Dominika Dudek5Department of Affective Disorders, Jagiellonian University Medical College, Krakow, PolandDepartment of Adult Psychiatry, Jagiellonian University Medical College, Krakow, PolandDepartment of Affective Disorders, Jagiellonian University Medical College, Krakow, PolandDepartment of Adult Psychiatry, Jagiellonian University Medical College, Krakow, PolandDepartment of Adult Psychiatry, Jagiellonian University Medical College, Krakow, PolandDepartment of Adult Psychiatry, Jagiellonian University Medical College, Krakow, PolandIntroductionEarly research on the pharmacotherapy for major depressive disorder (MDD) has largely focused on symptomatic improvements, whereas this focus has shifted to functioning and quality of life in recent years. Studies have confirmed that antidepressants generally improve the functional outcomes in MDD, but very few works have compared the efficacies of specific drugs. The present work aims to compare the impacts of trazodone once-a-day extended-release (XR) vs selective serotonin reuptake inhibitors (SSRIs) on the health status and quality of life in MDD.MethodsData were gathered from 180 subjects through a naturalistic observation study of trazodone effectiveness in depression (TED) and analyzed. The TED study participants received trazodone XR of SSRIs in flexible doses for 12 weeks. The health status and health-related quality of life (HRQoL) were evaluated using the EQ-5D-5L tool at baseline as well as 2, 4, 8, and 12 weeks.ResultsAt baseline, the subjects treated with trazodone XR vs SSRIs presented similar health status profiles and HRQoL values with respect to the mobility, self-care, and anxiety/depression dimensions along with lower scores for the usual activities, pain/discomfort, overall HRQoL, and health status. Both trazodone XR and SSRIs improved the health status and HRQoL of the MDD patients at all subsequent timepoints. Compared to SSRIs, trazodone XR provided greater improvements in terms of the self-care, usual activities, pain/discomfort, and anxiety/depression measures and more often improved participant overall health status and HRQoL. More participants reported mixed changes in their health status and HRQoL in the SSRI group than the trazodone XR group.DiscussionHealth status and HRQoL improved in both treatment arms, with preferable scores in trazodone XR vs. SSRIs group.https://www.frontiersin.org/articles/10.3389/fphar.2024.1525498/fulltrazodoneselective serotonin reuptake inhibitorsmajor depressive disorderquality of lifeEQ-5D-5L |
| spellingShingle | Marcin Siwek Adrian Andrzej Chrobak Anna Julia Krupa Aleksandra Gorostowicz Andrzej Juryk Dominika Dudek Trazodone effectiveness in depression: impacts of trazodone extended release vs SSRIs on the health status and quality of life of patients with major depressive disorder Frontiers in Pharmacology trazodone selective serotonin reuptake inhibitors major depressive disorder quality of life EQ-5D-5L |
| title | Trazodone effectiveness in depression: impacts of trazodone extended release vs SSRIs on the health status and quality of life of patients with major depressive disorder |
| title_full | Trazodone effectiveness in depression: impacts of trazodone extended release vs SSRIs on the health status and quality of life of patients with major depressive disorder |
| title_fullStr | Trazodone effectiveness in depression: impacts of trazodone extended release vs SSRIs on the health status and quality of life of patients with major depressive disorder |
| title_full_unstemmed | Trazodone effectiveness in depression: impacts of trazodone extended release vs SSRIs on the health status and quality of life of patients with major depressive disorder |
| title_short | Trazodone effectiveness in depression: impacts of trazodone extended release vs SSRIs on the health status and quality of life of patients with major depressive disorder |
| title_sort | trazodone effectiveness in depression impacts of trazodone extended release vs ssris on the health status and quality of life of patients with major depressive disorder |
| topic | trazodone selective serotonin reuptake inhibitors major depressive disorder quality of life EQ-5D-5L |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2024.1525498/full |
| work_keys_str_mv | AT marcinsiwek trazodoneeffectivenessindepressionimpactsoftrazodoneextendedreleasevsssrisonthehealthstatusandqualityoflifeofpatientswithmajordepressivedisorder AT adrianandrzejchrobak trazodoneeffectivenessindepressionimpactsoftrazodoneextendedreleasevsssrisonthehealthstatusandqualityoflifeofpatientswithmajordepressivedisorder AT annajuliakrupa trazodoneeffectivenessindepressionimpactsoftrazodoneextendedreleasevsssrisonthehealthstatusandqualityoflifeofpatientswithmajordepressivedisorder AT aleksandragorostowicz trazodoneeffectivenessindepressionimpactsoftrazodoneextendedreleasevsssrisonthehealthstatusandqualityoflifeofpatientswithmajordepressivedisorder AT andrzejjuryk trazodoneeffectivenessindepressionimpactsoftrazodoneextendedreleasevsssrisonthehealthstatusandqualityoflifeofpatientswithmajordepressivedisorder AT dominikadudek trazodoneeffectivenessindepressionimpactsoftrazodoneextendedreleasevsssrisonthehealthstatusandqualityoflifeofpatientswithmajordepressivedisorder |